{"analyses":[{"ciLowerLimit":"2.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"30.2","groupIds":["OG000"],"nonInferiorityComment":"The secondary analysis of the secondary outcome, ORR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with ORR will be presented with exact 95% confidence intervals.","nonInferiorityType":"OTHER","paramType":"Proportion","paramValue":"11.5"},{"ciLowerLimit":"4.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"34.9","groupDescription":"The secondary analysis of the secondary outcome, ORR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with ORR will be presented with exact 95% confidence intervals.","groupIds":["OG001"],"nonInferiorityType":"OTHER","paramType":"Proportion","paramValue":"15.4"},{"ciLowerLimit":"4.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"34.9","groupDescription":"The secondary analysis of the secondary outcome, ORR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with ORR will be presented with exact 95% confidence intervals.","groupIds":["OG002"],"nonInferiorityType":"OTHER","paramType":"Proportion","paramValue":"15.4"},{"ciLowerLimit":"0.1","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"19.6","groupDescription":"The secondary analysis of the secondary outcome, ORR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with ORR will be presented with exact 95% confidence intervals.","groupIds":["OG003"],"nonInferiorityType":"OTHER","paramType":"Proportion","paramValue":"3.8"},{"ciLowerLimit":"4.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"34.9","groupDescription":"The secondary analysis of the secondary outcome, ORR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with ORR will be presented with exact 95% confidence intervals.","groupIds":["OG004"],"nonInferiorityType":"OTHER","paramType":"Proportion","paramValue":"15.4"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"26"}],"units":"Participants"}],"description":"This will be assessed using CT scan evidence according to modified RECIST 1.1 criteria reporting. Scans will be undertaken every 6 weeks. Analysis will be timed from study entry using the baseline CT scan results until completion of treatment cycles, confirmed disease progression or death - whichever comes first.\n\nComplete response (CR): disappearance of all target and non-target lesions with no evidence of tumour elsewhere Partial response (PR): reduction of at least 30% in the sum of all measurements with no evidence of significant disease progression in non-target lesions or new lesions Progressive disease (PD): 1: increase of at least 20% in the sum of all measurements compared with the previous best response, 2: appearance of one or more significant (overall 20% increase in tumour diameters) new lesions, 3: significant increase in target lesions Stable disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD","groups":[{"description":"Rucaparib in DNA damage sensitive relapsed mesothelioma","id":"OG000","title":"MiST-1"},{"description":"Abemaciclib in p16INK4A negative mesothelioma","id":"OG001","title":"MiST-2"},{"description":"Pembrolizumab and bemcentinib in relapsed mesothelioma","id":"OG002","title":"MiST-3"},{"description":"Atezolizumab and Bevacizumab in relapsed mesothelioma","id":"OG003","title":"MiST-4"},{"description":"Dostarlimab and Niraparib in Patients with Platinum Sensitive Relapsed Mesothelioma","id":"OG004","title":"MiST-5"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Objective Response Rate (ORR) at 24 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.","type":"SECONDARY","unitOfMeasure":"Participants"}